Therapeutic Monoclonal Antibodies. from Bench to Clinic

• 70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. 
• First book to address the discovery and development of antibody therapeutics in their entirety.
• Most chapters contain experimental data to illustrate the principles described in them.
• Authors provide detailed methodologies that readers can take away with them and use in their own laboratories
  

Contents

FOREWORD.

PREFACE.

CONTRIBUTORS.

PART I ANTIBODY BASICS.

• 1. Therapeutic Monoclonal Antibodies: Past, Present, and Future (William R. Strohl).
• 2. Antibody Molecular Structure (Robyn L. Stanfield and Ian A. Wilson).
• 3. Glycosylation of Therapeutic IgGs (Yusuke Mimura, Roy Jefferis, Yuka Mimura-Kimura, Jodie Abrahams, and Pauline M. Rudd).
• 4. Antibody Databases and Tools: The IMGTw Experience (Marie-Paule Lefranc).

PART II ANTIBODY SOURCES.

• 5. Human Antibodies from Transgenic Mice (Nils Lonberg).
• 6. Rabbit Hybridoma (Weimin Zhu and Guo-Liang Yu).
• 7. Human Antibody Repertoire Libraries (David Lowe and Tristan J. Vaughan).

PART III IN VITRO DISPLAY TECHNOLOGY.

• 8. Antibody Phage Display (Michael Hust, Holger Thie, Thomas Schirrmann, and Stefan Dübel).
• 9. Yeast Surface Display (Jennifer L. Lahti and Jennifer R. Cochran).
• 10. Ribosomal Display (George Thom).
• 11. Bacterial Display of Antibodies (Thomas J. Van Blarcom and Barrett R. Harvey).
• 12. Antibody Selection from Immunoglobulin Libraries Expressed in Mammalian Cells (Ernest S. Smith and Maurice Zauderer).

PART IV ANTIBODY ENGINEERING.

13. Antibody Engineering: Humanization, Affinity Maturation, and Selection Techniques (Juan C. Almagro and William R. Strohl).

14. Modulation of Serum Protein Homeostasis and Transcytosis by the Neonatal Fc Receptor (William F. Dall’Acqua and Herren Wu).

15. Engineering the Antibody Fc Region for Optimal Effector Function (Greg A. Lazar and John R. Desjarlais).

PART V PHYSIOLOGY AND IN VIVO BIOLOGY.

• 16. Antibody-Complement Interaction (Kileen L. Mershon and Sherie L. Morrison).
• 17. Bacteria Immunoglobulin-Binding Proteins: Biology and Practical Applications (Leslie Cope and Tessie McNeely).
• 18. Immunogenicity Screening Using in Silico Methods: Correlation between T-Cell Epitope Content and Clinical Immunogenicity of Monoclonal Antibodies (Si-Han Hai, Julie A. McMurry, Paul M. Knopf, William Martin, and Anne S. De Groot).
• 19. Monoclonal Antibody Pharmacokinetics and Pharmacodynamics (Christopher R. Gibson, Punam Sandhu, and William D. Hanley).
• 20. Biodistribution and Imaging (Tove Olafsen and Anna M. Wu).
• 21. Antibodies and the Blood-Brain Barrier (Angela R. Jones and Eric V. Shusta).

PART VI ANTIBODY CHARACTERIZATION.

• 22. Determination of Equilibrium Dissociation Constants (Robin E. Ernst, Katrina N. High, Tom R. Glass, and Qinjian Zhao).
• 23. Molecular and Functional Characterization of Monoclonal Antibodies (Qinjian Zhao, Terrance A. Stadheim, Lorenzo Chen, and Michael W. Washabaugh).
• 24. Characterization of Heterogeneity in Monoclonal Antibody Products (Yang Wang, Michael W. Washabaugh, and Qinjian Zhao).

PART VII ANTIBODY EXPRESSION.

• 25. Antibody Expression in Mammalian Cells (Fubao Wang, Lorenzo Chen, Neal Connors, and Henryk Mach).
• 26. Production of Antibodies in Pichia pastoris (Juergen H. Nett).
• 27. Production of Antibody Fab0 Fragments in E. coli (David P. Humphreys and Leigh Bowering).
• 28. Production of Human Therapeutic Monoclonal Antibodies in Chicken Eggs (Lei Zhu and Robert J. Etches).
• 29. Production of Antibodies in Plants (Kevin M. Cox, Jeffrey T. Regan, Jason D. Sterling, Vincent P. M. Wingate, and Lynn F. Dickey).

PART VIII THERAPEUTIC ANTIBODIES.

• 30. The Formulation and Delivery of Monoclonal Antibodies (Vikas K. Sharma, Hung-Wei Chih, Randall J. Mrsny, and Ann L. Daugherty).
• 31. Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates (Ningyan Zhang, Brent R. Williams, Ping Lu, Zhiqiang An, and Chen-Ni Chin).
• 32. Follow-On Protein Products: What, Where, When, How (Brent R. Williams and William R. Strohl).
• 33. Monomeric Fc Fusion Molecules (Jennifer A. Dumont, Susan C. Low, Robert T. Peters, and Alan J. Bitonti).
• 34. Radioimmunotherapy: Current Status and Future Directions (Neeta Pandit-Taskar and Chaitanya R. Divgi).
• 35. Antibody-Drug Conjugate Therapy (Stephen C. Alley, Dennis Benjamin, and Che-Leung Law).

ABBREVIATIONS.

INDEX.

Author Information

Zhiqiang An, PhD, is the Chief Scientific Officer of Epitomics, Inc., in Burlingame, California. Previously, he was Director of Biologics Research at Merck Research Laboratories, West Point, Pennsylvania. Dr. An started his biotech/pharmaceutical career at Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts. He received a doctor of philosophy degree from the University of Kentucky, Lexington, followed by postdoctoral training at the University of Wisconsin–Madison.